Compare

Semnur Pharmaceuticals, Inc. vs NeuroSense Therapeutics Ltd. vs Alzamend Neuro, Inc. vs Inhibitor Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Semnur Pharmaceuticals, Inc. SMNR	NeuroSense Therapeutics Ltd. NRSN	Alzamend Neuro, Inc. ALZN	Inhibitor Therapeutics, Inc. INTI
Year ended	2025-12-31	2025-12-31	2026-04-30	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$160.42M	-$11.12M	-$8.77M	-$3.30M
EPS (Diluted)	-$0.78	-$0.44	-$2.63	-$0.02
Operating cash flow	-$5.87M	-$7.67M	-$8.07M	-$3.23M
Free cash flow	n/a	-$7.68M	n/a	n/a
Cash & equivalents	$20.0K	$166.0K	$710.7K	$2.38M
Total assets	$1.35M	$1.03M	$2.08M	$2.51M
Total liabilities	$22.10M	$2.59M	$1.35M	$3.80M
Shareholders' equity	-$20.75M	-$1.56M	$733.2K	-$1.29M
Return on year-end equity	n/a	n/a	n/m	n/a
Shares outstanding	230.21M	32.56M	4.26M	172.57M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Semnur Pharmaceuticals, Inc.	NeuroSense Therapeutics Ltd.	Alzamend Neuro, Inc.	Inhibitor Therapeutics, Inc.
Latest	n/a	n/a	n/a	$0 Ended 2021-12-31
1 year earlier	n/a	n/a	n/a	$0 Ended 2020-12-31
2 years earlier	n/a	n/a	n/a	$0 Ended 2019-12-31
3 years earlier	n/a	n/a	n/a	$0 Ended 2018-12-31
4 years earlier	n/a	n/a	n/a	$0 Ended 2017-12-31